News Search Results
Jul 24, 2025, 07:00 ET Corero Network Security Leads in 2025 SPARK Matrix With Higher Customer Impact
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), the DDoS protection specialists, today announced it has been named both a Leader and an Emerging Innovator in the 2025 SPARK Matrix
More news about: Corero Network Security
Jul 23, 2025, 11:14 ET DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience
$17 from $33 and stated that ALTO-100's data raises questions around the Company's overall biomarker approach to CNS disorders and psychiatry. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class
More news about: Faruqi & Faruqi, LLP
Jul 23, 2025, 08:00 ET Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid Use Disorder
and death have occurred in association with buprenorphine. Warn patients of the potential danger of self-administration of benzodiazepines or other CNS depressants while under treatment with SUBLOCADE. Risk of Serious Injection Site Reactions: Likelihood of may increase with inadvertent
More news about: Indivior PLC
Jul 22, 2025, 11:19 ET Natus announces Moberg CNS integration with NeuroWorks for advanced EEG
NeuroWorks, the Moberg CNS Monitor enhances EEG visibility, offering real-time EEG, annotations, and video in one platform to support comprehensive, data-driven patient care. Already trusted for continuous EEG monitoring in critically ill ICU patients, this integration with the Moberg CNS expands the presence
More news about: Natus Medical Incorporated
Jul 22, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain Officers - ANRO
pro-neurogenesis/neuroplasticity mechanism of action" and has stated that the Company "believe[s] binds a receptor not targeted by other [central nervous system ("CNS")] therapeutics, which would make it first-in-class if approved." On January 12, 2024, Alto filed a registration
More news about: Pomerantz LLP
Jul 22, 2025, 08:19 ET Hoth Therapeutics Signs VA Research Deal to Advance GDNF as Breakthrough Therapy for Obesity and Fatty Liver - Side-by-Side Study vs. Semaglutide Begins
marks the first pharmacologic test of GDNF in human liver-engrafted mice — setting the stage for potential first-in-class metabolic applications beyond CNS indications. "This landmark agreement allows a real-world, controlled comparison of GDNF's metabolic effects alongside semaglutide — the current
More news about: Hoth Therapeutics, Inc.
Jul 21, 2025, 20:00 ET Neuraxpharm continues international expansion with launch of Neuraxpharm Australia
Avendran Naidu appointed Head of Commercial to lead new affiliate CNS specialist continues growth strategy outside Europe to commercialise CNS treatments, including Nuvigil® (armodafinil), Modavigil® (modafinil), and
More news about: Neuraxpharm
Jul 21, 2025, 06:30 ET Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naïve ALK-positive NSCLC
for central nervous system (CNS) penetrance to improve treatment options for patients with brain metastases, and to avoid inhibition of the structurally related tropomyosin receptor kinase (TRK) family. Together, these characteristics have the potential to avoid TRK-related CNS adverse events seen with
More news about: Nuvalent, Inc.
Jul 18, 2025, 06:32 ET Weekly Recap: 14 Health Press Releases You Need to See
Illimis Therapeutics Closes 58 billion KRW ($42 million) Series B Financing to accelerate CNS and Immune Disease Drug Development via GAIA Platform The proceeds will be used to accelerate the development of GAIA-based Alzheimer's
More news about: PR Newswire
Jul 17, 2025, 16:13 ET COHEN & STEERS REPORTS RESULTS FOR SECOND QUARTER 2025
YORK, July 17, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported its results for the quarter ended June 30, 2025. The earnings release along with the accompanying earnings
More news about: Cohen & Steers, Inc.
Jul 17, 2025, 11:00 ET BrainXell, Inc. Strengthens Executive Leadership with Paul Marcus and Dr. Su-Chun Zhang
Su-Chun Zhang, an internationally recognized expert in stem cell neuroscience whose groundbreaking work in human iPSC differentiation and CNS development underpins BrainXell's core technology platform. He now serves as Advising Chief Scientific Officer. "We are incredibly fortunate
More news about: BrainXell, Inc.
Jul 16, 2025, 13:25 ET G-Protein Coupled Receptor (GPCR) Targeting Technologies Market on the Rise
types include functional and binding assays, while product types range from cell lines to detection kits. Applications span cancer, cardiovascular, CNS, and respiratory diseases. The report also covers regional markets across North America, Europe,
More news about: BCC Research LLC
Jul 14, 2025, 07:00 ET Corero Network Security Partners with IP Networks to Expand Reach of Adaptive DDoS Protection Across North America
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), the distributed denial of service (DDoS) protection specialists, today announced a strategic partnership with
More news about: Corero Network Security
Jul 14, 2025, 03:38 ET Illimis Therapeutics Closes 58 billion KRW ($42 million) Series B Financing to accelerate CNS and Immune Disease Drug Development via GAIA Platform
Illimis Therapeutics is a pioneering biotechnology company at the forefront of developing innovative therapies for challenging central nervous system (CNS) and immune-related diseases. The company's core strength lies in its proprietary GAIA (Gas6-mediated Anti-Inflammatory Adaptor) platform. This cutting-edge
More news about: Illimis Therapeutics
Jul 10, 2025, 17:46 ET Comprehensive Lewy Body Dementia Market Analysis of Evolving Trends and Anticipated Growth Trajectory During the Forecast Period (2025-2034) | DelveInsight
Lewy Body Dementia Market Report Neflamapimod, an investigational central nervous system (CNS) therapy developed by CervoMed and originally licensed from Vertex Pharmaceuticals, has been granted Fast Track designation (FTD) by the FDA for the
More news about: DelveInsight Business Research, LLP
Jul 10, 2025, 11:00 ET BrainXell, Inc. Appoints Katherine Vega Stultz as Chief Executive Officer and Board Director
July 10, 2025 /PRNewswire/ -- BrainXell, Inc., a leading biotechnology company developing iPSC-based CNS disease models and regenerative cell therapies, announces the appointment of Katherine Vega Stultz as its new Chief Executive
More news about: BrainXell, Inc.
Jul 10, 2025, 09:20 ET Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up
and CEO of Nuvation Bio. "These updates address critical needs for patients across their treatment journeys, especially with the prevalence of CNS involvement for those living with ROS1+ NSCLC. Additionally, this version builds further upon a previous guideline update that importantly highlights
More news about: USA News Group
Jul 10, 2025, 08:30 ET BRENIG THERAPEUTICS ANNOUNCES APPOINTMENTS OF DAVID L. LUCCHINO AS CEO AND TIEN DAM, M.D., AS CHIEF MEDICAL OFFICER, EXPANDS PIPELINE
small-molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2)—a key protein implicated in the pathogenesis of Parkinson's disease. Designed to maximize CNS exposure while minimizing peripheral activity, BT-267 offers a differentiated profile aimed at reducing off-target and systemic side effects. BT-267
More news about: Brenig Therapeutics Inc.
Jul 10, 2025, 08:00 ET Transcend Therapeutics Receives Breakthrough Therapy Designation for TSND-201 (methylone) for the Treatment of PTSD
5HT-2a (i.e., not hallucinogenic). Transcend is developing TSND-201 as a rapid-acting and durable treatment for PTSD and other central nervous system (CNS) indications. TSND-201 is an investigational medication. About PTSDPTSD is a mental health condition that can occur after experiencing
More news about: Transcend Therapeutics
Jul 10, 2025, 07:00 ET Corero Network Security Enables Cloud-Native DDoS Orchestration in Akamai Compute
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), the distributed denial of service (DDoS) protection specialists, today announced that the orchestration plane of its flagship
More news about: Corero Network Security
Jul 09, 2025, 16:30 ET Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for June 2025
YORK, July 9, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $88.9 billion as of June 30, 2025,
More news about: Cohen & Steers, Inc.
Jul 09, 2025, 16:25 ET Cohen & Steers, Inc. to Release Second Quarter 2025 Results on July 17, 2025
YORK, July 9, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced that it expects to release second quarter 2025 results after the market closes on Thursday, July 17, 2025. The
More news about: Cohen & Steers, Inc.
Jul 09, 2025, 12:00 ET Zhimeng Biopharma's Next-Generation KCNQ2/3 Potassium Channel Opener Receives Clinical Trial Approval for ALS Phase 2/3 Study
Inc. ("Zhimeng Biopharma"), a clinical-stage biopharmaceutical company dedicated to innovative drug development for liver and central nervous system (CNS) diseases, today announced that its self-discovered next-generation KCNQ2/3 potassium channel opener, CB03-154, has received an approval from the Center
More news about: Shanghai Zhimeng Biopharma, Inc.
Jul 09, 2025, 08:00 ET Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial
standard approval. Other clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the
More news about: Kazia Therapeutics Limited
Jul 08, 2025, 23:28 ET 코헨 앤드 스티어스, 한국 기관 비즈니스 총괄에 신윤현 (Andrew Shin) 부사장 임명
https://www.cohenandsteers.com주식 심벌: 뉴욕증권거래소(NYSE): CNS 미래예측진술 본 보도자료 및 코헨 앤드 스티어스가 향후 발표할 수 있는 기타 진술에는 1933년 증권법 제27A조(수정 조항) 및 1934년 증권거래법 제21E조(수정 조항)에 따른 미래예측진술이 포함될 수 있으며, 이러한 진술에는 회사의 운영
More news about: Cohen & Steers, Inc.